

General structure and information for a letter of support for the MMS EML application

The meeting of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines will be coordinated from WHO Headquarters, Geneva and held virtually on 21 June to 2 July 2021 to revise and update the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc).

The applications to be considered by the Expert Committee during the meeting are published on this website <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/23rd-expert-committee> . A22 refers to the MMS application.

Comments must be provided in PDF format, and should clearly reference the application to which they apply in the file name.

The deadline for submission of comments is **21 May 2021**.

Letters of support can come from anyone, including individuals, organizations or countries. Below is some guidance on the typical structure. All comments received will be published on this webpage and will be provided to the Expert Committee for their consideration.

- **Email to:** The Secretary of the Expert Committee, Dr Benedikt Huttner, to emlsecretariat@who.int . The WHO Expert Committee on the Selection and Use of Essential Medicines, Department of Essential Medicines and Health Products, 20 Via Appia, CH-1211 Geneva 27, Switzerland
- **Intent of the letter:** Support in favour of adding Multiple Micronutrient Supplements for pregnant women as an item on the WHO List of Essential Medicines.
- **Sender:** indicate whether the letter is sent on behalf of an organization or ministry. Introduce the organization or authors of the letter and why they are in a position to comment (e.g., expertise in the area, role in policy development or programme implementation).
- **Describe a public health problem** in which MMS can help improve outcomes and if possible, how this relates to a particular context (e.g., prevalence of low birth weight or preterm birth in a specific country or other outcomes that could be impacted by MMS).
- Describe how the use of MMS can **help meet global, local or organizational targets/goals** in preventing adverse pregnancy outcomes. The [NI calculator](#) may be a useful tool in estimating the impact of the intervention in specific countries.
- **Describe the solid evidence base** demonstrating the effectiveness of MMS over IFA, referring to the meta-analyses described in the application itself.
- Summarize why adding MMS to the EML is an important step in achieving goals on maternal nutrition, reducing adverse pregnancy outcomes or improving health equity.